Nothing Special   »   [go: up one dir, main page]

WO2011103490A3 - INTEGRIN αVβ8 NEUTRALIZING ANTIBODY - Google Patents

INTEGRIN αVβ8 NEUTRALIZING ANTIBODY Download PDF

Info

Publication number
WO2011103490A3
WO2011103490A3 PCT/US2011/025514 US2011025514W WO2011103490A3 WO 2011103490 A3 WO2011103490 A3 WO 2011103490A3 US 2011025514 W US2011025514 W US 2011025514W WO 2011103490 A3 WO2011103490 A3 WO 2011103490A3
Authority
WO
WIPO (PCT)
Prior art keywords
neutralizing antibody
ανβ8
integrin αvβ8
αvβ8
integrin
Prior art date
Application number
PCT/US2011/025514
Other languages
French (fr)
Other versions
WO2011103490A2 (en
Inventor
Stephen Nishimura
Jianlong Lou
Jody Lynn Baron
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR112012020790-3A priority Critical patent/BR112012020790B1/en
Priority to EP23151118.9A priority patent/EP4219560A3/en
Priority to MX2012009564A priority patent/MX342270B/en
Priority to SG2012060893A priority patent/SG183356A1/en
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Priority to KR1020127024165A priority patent/KR101838763B1/en
Priority to CN201180018213.1A priority patent/CN102834412B/en
Priority to CA2790488A priority patent/CA2790488C/en
Priority to RU2012139829/10A priority patent/RU2565539C2/en
Priority to JP2012554069A priority patent/JP2013520173A/en
Priority to US13/580,105 priority patent/US9290572B2/en
Priority to EP11745373.8A priority patent/EP2536762A4/en
Priority to AU2011217848A priority patent/AU2011217848B8/en
Publication of WO2011103490A2 publication Critical patent/WO2011103490A2/en
Publication of WO2011103490A3 publication Critical patent/WO2011103490A3/en
Priority to US15/003,642 priority patent/US9845357B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)

Abstract

The present invention relates to ανβ8 antagonists, anti-ανβ8 antibodies or immunoconjugates for reducing ΤGFβ activation in an individual. Further provided are compositions comprising one of the ανβ8 antagonists, anti-ανβ8 antibodies or immunoconjugates, methods for using the compositions, and related subject matter.
PCT/US2011/025514 2010-02-18 2011-02-18 INTEGRIN αVβ8 NEUTRALIZING ANTIBODY WO2011103490A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CN201180018213.1A CN102834412B (en) 2010-02-18 2011-02-18 Integin αV β 8 neutralizing antibody
MX2012009564A MX342270B (en) 2010-02-18 2011-02-18 Integrin î±vî²8 neutralizing antibody.
SG2012060893A SG183356A1 (en) 2010-02-18 2011-02-18 INTEGRIN aVß8 NEUTRALIZING ANTIBODY
RU2012139829/10A RU2565539C2 (en) 2010-02-18 2011-02-18 INTEGRIN ανβ8 NEUTRALISING ANTIBODIES
KR1020127024165A KR101838763B1 (en) 2010-02-18 2011-02-18 INTEGRIN αⅤβ8 NEUTRALIZING ANTIBODY
EP23151118.9A EP4219560A3 (en) 2010-02-18 2011-02-18 Integrin alpha v beta 8 neutralizing antibody
CA2790488A CA2790488C (en) 2010-02-18 2011-02-18 Integrin .alpha.v.beta.8 neutrilizing antibody
BR112012020790-3A BR112012020790B1 (en) 2010-02-18 2011-02-18 ISOLATED ANTIBODY ANTI-INTEGRIN ALFAVBETA8 AND PHARMACEUTICAL COMPOSITION
JP2012554069A JP2013520173A (en) 2010-02-18 2011-02-18 Integrin αvβ8 neutralizing antibody
US13/580,105 US9290572B2 (en) 2010-02-18 2011-02-18 Integrin α-Vβ8 neutralizing antibody
EP11745373.8A EP2536762A4 (en) 2010-02-18 2011-02-18 INTEGRIN alpha V beta 8 NEUTRALIZING ANTIBODY
AU2011217848A AU2011217848B8 (en) 2010-02-18 2011-02-18 Integrin aVB8 neutralizing antibody
US15/003,642 US9845357B2 (en) 2010-02-18 2016-01-21 Integrin αvβ8 neutralizing antibody

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30574910P 2010-02-18 2010-02-18
US61/305,749 2010-02-18
US201061428814P 2010-12-30 2010-12-30
US61/428,814 2010-12-30

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/580,105 A-371-Of-International US9290572B2 (en) 2010-02-18 2011-02-18 Integrin α-Vβ8 neutralizing antibody
US15/003,642 Division US9845357B2 (en) 2010-02-18 2016-01-21 Integrin αvβ8 neutralizing antibody

Publications (2)

Publication Number Publication Date
WO2011103490A2 WO2011103490A2 (en) 2011-08-25
WO2011103490A3 true WO2011103490A3 (en) 2011-10-27

Family

ID=44483602

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/025514 WO2011103490A2 (en) 2010-02-18 2011-02-18 INTEGRIN αVβ8 NEUTRALIZING ANTIBODY

Country Status (12)

Country Link
US (2) US9290572B2 (en)
EP (2) EP2536762A4 (en)
JP (2) JP2013520173A (en)
KR (1) KR101838763B1 (en)
CN (2) CN105315370A (en)
AU (1) AU2011217848B8 (en)
BR (1) BR112012020790B1 (en)
CA (1) CA2790488C (en)
MX (1) MX342270B (en)
RU (1) RU2565539C2 (en)
SG (1) SG183356A1 (en)
WO (1) WO2011103490A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2790488C (en) * 2010-02-18 2018-09-25 The Regents Of The University Of California Integrin .alpha.v.beta.8 neutrilizing antibody
EP2744823B1 (en) * 2011-08-17 2017-08-02 The Regents of the University of California Antibodies that bind integrin alpha-v beta-8
JP2015517463A (en) * 2012-05-02 2015-06-22 ニューヨーク・ユニバーシティ Methods of treating and preventing S. aureus infection and related conditions
EP3747907A3 (en) * 2013-04-01 2021-02-24 The Regents of the University of California Methods and compositions for treating and preventing disease associated with avb8 integrin
LT3157561T (en) * 2014-06-17 2020-07-10 Medimmune Limited Improved alpha-v beta-8 antibodies
EP3009147A1 (en) 2014-10-16 2016-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant glioblastoma
WO2017182834A1 (en) 2016-04-19 2017-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating resistant glioblastoma
AU2017335991B2 (en) 2016-09-29 2023-07-06 The Regents Of The University Of California Neutralizing antibodies to the αVβ8 integrin complex for immunotherapy
MX2021002690A (en) * 2018-09-07 2021-05-12 Pfizer Anti-avb8 antibodies and compositions and uses thereof.
WO2020210650A1 (en) * 2019-04-12 2020-10-15 Medimmune, Llc Neutralization of tgf-beta or alpha-v-beta-8 integrin for s. aureus infections
CN115151305A (en) * 2020-01-27 2022-10-04 免疫医疗有限公司 Anti- α v β 8 integrin antibodies for the treatment of kidney disease
WO2024056668A1 (en) 2022-09-12 2024-03-21 Institut National de la Santé et de la Recherche Médicale New anti-itgb8 antibodies and its uses thereof
WO2024073372A2 (en) * 2022-09-29 2024-04-04 The Brigham And Women's Hospital, Inc. Blocking itgb8 in neurodegenerative disease
CN117126282B (en) * 2023-10-26 2024-01-12 迈威(上海)生物科技股份有限公司 Antibody and application thereof in preparation of medicine for blocking combination of alpha v beta 8 and Latent TGF-beta
CN117143241B (en) * 2023-10-26 2024-02-23 迈威(上海)生物科技股份有限公司 Monoclonal antibodies that specifically bind to human integrin protein ITGAV/ITGB8

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635601A (en) * 1991-03-14 1997-06-03 Genentech, Inc. Beta-8 integrin subunit antibodies

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (en) 1978-01-06 1979-08-03 David Bernard DRYER FOR SCREEN-PRINTED SHEETS
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5204445A (en) * 1988-10-03 1993-04-20 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE69029036T2 (en) 1989-06-29 1997-05-22 Medarex Inc SPECIFIC REAGENTS FOR AIDS THERAPY
ATE356869T1 (en) 1990-01-12 2007-04-15 Amgen Fremont Inc FORMATION OF XENOGENE ANTIBODIES
KR0149181B1 (en) 1990-06-29 1998-08-17 데이비드 알, 맥지 Melanin production by transformed microorganisms
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0814159T3 (en) 1990-08-29 2005-10-24 Genpharm Int Transgenic, non-human animals capable of forming heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
PT719859E (en) * 1994-12-20 2003-11-28 Merck Patent Gmbh ANTI-ALPHA MONOCLONAL ANTIBODY V-INTEGRINA
CN1168741C (en) * 1998-01-23 2004-09-29 默克专利股份有限公司 Monoclonal antibody anti alpha, V-integrin and it use to inhibit & alpha, V & beta, 6-integrain attachment to fibronectine
US6160099A (en) 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
ES2146552B1 (en) * 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra INHIBITING PEPTIDES OF TGF / 31
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
AR038568A1 (en) 2002-02-20 2005-01-19 Hoffmann La Roche ANTI-A BETA ANTIBODIES AND ITS USE
AU2003295411A1 (en) 2002-11-07 2004-06-03 Celltech R & D Human monoclonal antibodies to heparanase
WO2004072266A2 (en) 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
US7354584B2 (en) 2003-04-11 2008-04-08 Medimmune, Inc. Recombinant IL-9 antibodies
EP1674480A4 (en) 2003-09-04 2007-06-20 Riken Antibody recognizing tgf-beta activation controlling region section
WO2005065348A2 (en) 2003-12-31 2005-07-21 Kalobios, Inc. Transactivation system for mammalian cells
SI1704166T1 (en) 2004-01-07 2015-06-30 Novartis Vaccines And Diagnostics, Inc. M-csf-specific monoclonal antibody and uses thereof
WO2005069970A2 (en) 2004-01-20 2005-08-04 Kalobios, Inc. Antibody specificity transfer using minimal essential binding determinants
RU2386638C2 (en) * 2004-03-31 2010-04-20 Дженентек, Инк. Humanised anti-tgf-beta-antibody
ES2881353T3 (en) 2004-11-16 2021-11-29 Humanigen Inc Exchange of immunoglobulin variable region cassettes
GB0520068D0 (en) * 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand
US20090175784A1 (en) * 2007-05-11 2009-07-09 Joshua Goldstein Anti-Alpha V Immunoliposome Composition, Methods, and Uses
RU2011111640A (en) 2008-08-29 2012-10-10 Симфоген А/С (Dk) ANTIBODIES AGAINST CD5
CA2790488C (en) * 2010-02-18 2018-09-25 The Regents Of The University Of California Integrin .alpha.v.beta.8 neutrilizing antibody
EP2744823B1 (en) * 2011-08-17 2017-08-02 The Regents of the University of California Antibodies that bind integrin alpha-v beta-8

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635601A (en) * 1991-03-14 1997-06-03 Genentech, Inc. Beta-8 integrin subunit antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Integrin alphaV, beta3 (PE).", US BIOLOGICAL TECHNICAL DATA SHEET. I7661-37E1, XP008166922, Retrieved from the Internet <URL:www.usbio.net/technicalSheet.php?item=I7661-37E1> [retrieved on 20110809] *
DATABASE UNIPROT [online] 9 February 2010 (2010-02-09), "Integrin beta-8.", XP008158697, Database accession no. P26012. *
MU ET AL.: "The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-betal.", J CELL BIOL, vol. 157, 2002, pages 493 - 507, XP055071726 *

Also Published As

Publication number Publication date
RU2565539C2 (en) 2015-10-20
KR101838763B1 (en) 2018-03-14
EP2536762A4 (en) 2014-01-01
CA2790488C (en) 2018-09-25
MX2012009564A (en) 2013-01-29
JP6212159B2 (en) 2017-10-11
BR112012020790B1 (en) 2021-09-28
US9290572B2 (en) 2016-03-22
BR112012020790A2 (en) 2016-05-03
JP2013520173A (en) 2013-06-06
US20130064837A1 (en) 2013-03-14
CN102834412B (en) 2016-01-20
AU2011217848A1 (en) 2012-09-13
AU2011217848B2 (en) 2015-08-27
RU2012139829A (en) 2014-03-27
SG183356A1 (en) 2012-09-27
EP2536762A2 (en) 2012-12-26
US9845357B2 (en) 2017-12-19
JP2016196457A (en) 2016-11-24
US20160137737A1 (en) 2016-05-19
EP4219560A2 (en) 2023-08-02
CA2790488A1 (en) 2011-08-25
AU2011217848B8 (en) 2015-09-24
EP4219560A3 (en) 2023-08-23
CN102834412A (en) 2012-12-19
KR20120137482A (en) 2012-12-21
CN105315370A (en) 2016-02-10
WO2011103490A2 (en) 2011-08-25
AU2011217848A8 (en) 2015-09-24
MX342270B (en) 2016-09-21

Similar Documents

Publication Publication Date Title
WO2011103490A3 (en) INTEGRIN αVβ8 NEUTRALIZING ANTIBODY
IL273607A (en) Humanized antibodies against liv-1, compositions comprising the same and uses thereof
IL265397B (en) Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
IL252154A0 (en) Anti-dr5 antibodies, compositions comprising the same and uses thereof
WO2010089411A3 (en) Pd-1 antibodies and pd-l1 antibodies and uses thereof
WO2012087962A3 (en) Anti-mesothelin antibodies and immunoconjugates
IL226383A0 (en) Anti-ccl20 antibodies, compositions comprising the same and uses thereof
MX345909B (en) Anti-fgfr3 antibodies and methods using same.
WO2013177055A3 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
MX2019006362A (en) Composition comprising two antibodies engineered to have reduced and increased effector function.
WO2011142858A3 (en) Chlorotoxin variants, conjugates, and methods for their use
IL236348A0 (en) Anti-jagged antibodies, compositions comprising the same and uses thereof
WO2014078268A8 (en) Anti-hemagglutinin antibodies and methods of use
WO2012024526A3 (en) Conjugates, particles, compositions, and related methods
IL225460A0 (en) Antibodies binding 191p4d12, compositions comprising the same and uses thereof
GB201218752D0 (en) Mineral complex, compositions thereof, and methods of using the same
WO2011133504A3 (en) Nanozymes, methods of making nanozymes, and methods of using nanozymes
EP2571982A4 (en) Antigen specific tregs and related compositions, methods and systems
WO2012080926A3 (en) Anti-notch1 antibodies
MY161601A (en) Films and compositions comprising the same
WO2011050188A8 (en) Anti-hepsin antibodies and methods using same
UA109148C2 (en) Compositions based on anti-vegfr-3 antibody
WO2012022734A3 (en) Anti-icam-1 antibodies and methods of use
EP2569006A4 (en) The n-domain of carcinoembryonic antigen and compositions, methods and uses thereof
WO2011140334A3 (en) Compounds, methods of making or identifying compounds, and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180018213.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11745373

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2790488

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2012554069

Country of ref document: JP

Ref document number: MX/A/2012/009564

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011217848

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2011745373

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011217848

Country of ref document: AU

Date of ref document: 20110218

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20127024165

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012139829

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 13580105

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012020790

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012020790

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120817